key: cord-0811509-hbmj2wyw
authors: Schalekamp, S.; Huisman, M.; van Dijk, R. A.; Boomsma, M.F.; Freire Jorge, P.J.; de Boer, W.S; Herder, G.J.M.; Bonarius, M.; Groot, O.A.; Jong, E.; Schreuder, A.; Schaefer-Prokop, C.M.
title: Model-based Prediction of Critical Illness in Hospitalized Patients with COVID-19
date: 2020-08-13
journal: Radiology
DOI: 10.1148/radiol.2020202723
sha: 1e3d14c8c9269a3f77c9d5554162832d20b5de08
doc_id: 811509
cord_uid: hbmj2wyw

BACKGROUND: The prognosis of hospitalized patients with severe coronavirus disease 2019 (COVID-19) is difficult to predict, while the capacity of intensive care units (ICUs) is a limiting factor during the peak of the pandemic and generally dependent on a country’s clinical resources. PURPOSE: To determine the value of chest radiographic findings together with patient history and laboratory markers at admission to predict critical illness in hospitalized patients with COVID-19. MATERIAL AND METHODS: In this retrospective study including patients from 7th March 2020 to 24(th) April 2020, a consecutive cohort of hospitalized patients with RT-PCR-confirmed COVID-19 from two large Dutch community hospitals was identified. After univariable analysis, a risk model to predict critical illness (i.e. death and/or ICU admission with invasive ventilation) was developed, using multivariable logistic regression including clinical, CXR and laboratory findings. Distribution and severity of lung involvement was visually assessed using an 8-point scale (chest radiography score). Internal validation was performed using bootstrapping. Performance is presented as an area under the receiver operating characteristic curve (AUC). Decision curve analysis was performed, and a risk calculator was derived. RESULTS: The cohort included 356 hospitalized patients (69 ±12 years, 237 male) of whom 168 (47%) developed critical illness. The final risk model’s variables included gender, chronic obstructive lung disease, symptom duration, neutrophil count, C-reactive protein level, lactate dehydrogenase level, distribution of lung disease and chest radiography score at hospital presentation. The AUC of the model was 0.77 (95% CI: 0.72-0.81, P < .001). A risk calculator was derived for individual risk assessment; Dutch COVID-19 risk model (see Appendix E2). At an example threshold of 0.70, 71 of 356 patients would be predicted to develop critical illness of which 59 (83%) would be true-positives. CONCLUSION: A risk model based on chest radiographic and laboratory findings obtained at admission was predictive of critical illness in hospitalized patients with coronavirus disease 2019. This risk calculator might be useful for triage of patients to the limited number of ICU beds/facilities.

The worldwide spread of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leading to coronavirus disease 2019 (COVID-19) caused more than 19 million confirmed cases and over 700,000 deaths up to August 9th, 2020 (1) . The majority of patients with COVID-19 present without any symptoms or only mild respiratory symptoms, not requiring hospital admission.

However, a proportion of patients are hospitalized because of systemic or severe respiratory symptoms (2) (3) (4) (5) of which a subgroup may undergo fast clinical deterioration requiring invasive ventilation and intensive care unit (ICU) treatment, with lethal outcome in the worst-case scenario.

This demand for ICU treatment exceeding the options of existing facilities lead to the mobilization of new ICUs, worldwide drastic actions of unprecedented social distancing and different degrees of lockdown to decrease the number of critically ill patients. A number of factors have been described that contribute to poor prognosis. Higher mortality rates occur with increasing age and presence of chronic comorbidities (6) (7) (8) . A wide spectrum of laboratory values have been linked to poor prognosis and risk of ICU admission (2-4, 6, 7, 9-15) .

Although some guidelines do not advise screening of patients suspected of COVID-19 with chest radiography or CT (16, 17) , imaging remains important for the diagnosis and risk stratification at admission, as in other types of pneumonia (5, (18) (19) (20) . In the previous severe acute respiratory syndrome epidemic in 2003 and Middle Eastern respiratory syndrome epidemic in 2012-2015, chest radiography findings were found to correlate with prognosis (21) (22) (23) (24) (25) .

Publications exploring prognostic markers for COVID-19 thus far largely focused on laboratory findings alone, considered the presence of any abnormality on chest radiography to be a risk factor, or utilized the longitudinal development of disease on thoracic CT. The body of knowledge regarding the complementary information of clinical, laboratory and chest radiography findings is limited.

Recently, a Chinese study was published including 1590 patients with COVID-19 of whom 131 (8%) I n P r e s s became critically ill, and therefore needed ICU admission or died. The authors presented a predictive risk-score based on 10 variables, showing good discrimination (AUC = 0.88) (26) .

The purpose of this study was to determine the prognostic value of the combined information of patient history, readily available laboratory markers, and chest radiography at admission to predict critical illness, defined as ICU admission for invasive ventilation and/or death, in hospitalized patients with known RT-PCT positive COVID-19.

In this retrospective cohort-study, inclusion took place in two large community teaching hospitals (Meander Medical Center, Amersfoort, the Netherlands; Isala Hospitals, Zwolle, the Netherlands)during the peak of the SARS-CoV-2 pandemic. The study was approved by the local institutional review boards of both hospitals, and written informed consent was waived (20-036, and 200435 ).

Using our hospital's COVID-19 registry, all consecutive patients between March 7th and April 24th 2020 suspected of COVID-19 on admission at the emergency department were derived. Patients that did not have a positive real-time reverse transcription polymerase chain reaction (RT-PCR) proven COVID-19 or patients that were not hospitalized were excluded. First RT-PCR tests were taken within 24 hours of hospital admission. If the first test was negative but clinical suspicion remained subsequent tests were performed.

Other exclusion criteria were no chest radiography on admission, transferred patients with uncertain onset of symptoms, status after pneumonectomy, and children (<18 years).

Medical records were reviewed to collect information on patient gender, age, comorbidities (hypertension as diagnosed by a physician, diabetes (either type 1 or type 2 diabetes), history of any type of cancer (present or previous), chronic obstructive lung disease (i.e. COPD or asthma) and cardiac diseases (i.e. ischemic heart disease and/or pre-existent cardiomyopathy)), days of symptoms prior to admission, and temperature at admission (in Celsius). From the blood samples obtained at emergency ward presentation, the following markers were collected: white blood cell (WBC) count, lymphocyte count (x10 9 /L), neutrophil granulocyte count (x10 9 /L), C-reactive protein (CRP in mg/L), and lactate dehydrogenase (LDH in IU/L). Neutrophil-to-lymphocyte ratio (NLR) was calculated from the blood samples. Ferritin, procalcitonin, D-dimer and fibrinogen were not part of the standard laboratory work-up at admission in both centers and were not included. Subsequent laboratory tests were not taken into account.

Chest radiographs obtained within 24 hours after emergency ward presentation were used for analysis. The collected radiographic features included a visual assessment of body habitus (evidently large vs. normal) and the distribution of lung abnormalities into predominantly central (i.e. perihilar), peripheral (i.e. attached to the pleural surface), or diffuse (i.e. both central and peripheral abnormalities). If other non-infectious extensive lung abnormalities, such as large tumors, extensive emphysema or fibrosis, were present in the image, these images were marked as images with preexisting lung disease. Furthermore, the chest radiograph was divided into 4 zones: right upper lung, left upper lung, right lower lung, left lower lung, using simple anatomic landmarks ( Figure 2) . Then, the extent of abnormal lung parenchyma was visually scored as 0 = no involvement, 1 = mild/moderate involvement (estimated involvement 0-50% of lung parenchyma), and 2 = severe involvement (estimated involvement >50% of lung parenchyma) per zone resulting in a score between 0 and 8 (chest radiography score). Chest radiographs were independently analyzed by a I n P r e s s chest radiologists (SS and CSP in hospital A, 5 and 25 years of experience, RvD in hospital B, 7 years of experience), blinded to laboratory values and patient outcome. A training session with representative cases was done to ensure a common understanding of the reading task. Image interpretations were done blinded for the clinical outcome, and no double readings were performed.

Critical illness was defined by admission to the ICU for invasive ventilation and/or death. Patients admitted to the COVID-19 cohort wards without the need for mechanical ventilation and alive at follow-up are referred to as non-critically ill in this study. The outcome was determined by reviewing the patient's records. Median follow-up time was 34 days (range, 12-53 days); no patients were lost to follow-up.

To achieve valid results for the chest radiography score and to reduce overfitting, a power analysis with 1-β = 0.8 (α=.05; 2-sided testing) resulted in a minimally required sample size of n=300.

Continuous data are presented as means with standard deviations or medians with ranges as appropriate. Categorical data are presented as proportions. For cases with a missing value (i.e., CRP, LDH, lymphocytes, neutrophils, and days of symptoms, 21/356, 6%), data were imputed using multiple imputation (27). Prior to imputation, data was analyzed to ensure the assumption missingness at random was reasonable. Univariable analyses were performed by means of a Chisquare Test, Mann-Whitney U Test or Student T-Test as appropriate. Variables for the multivariable logistic regression were chosen based on univariable testing with P<.1 and clinical reasoning to prevent multiple testing.

Multivariable logistic regression (backward elimination with fractional polynomial transformation) was performed with P<.2 for the inclusion of covariables and P<.05 for fractional polynomial I n P r e s s transformation of variables. Fractional polynomial transformation was chosen because of the exploratory character of the study (28) . Discrimination performance was determined by the area under the receiver operating characteristic curve (AUC). Calibration was assessed graphically (29) .

Internal validation was done by non-parametric bootstrapping (k=2000) for the AUC (30).

A decision curve for our model was included to aid clinical decision making based on a risk threshold preference (31). A decision curve is a plot of standardized net benefit against the risk probability threshold. The net benefit describes the difference between the benefit of true positive calls (correct prediction of critical illness) and the harm of false positives, the latter being adjusted to how much a false positive outcome weighs compared to a true positive call (e.g., if the harms of a false positive outcome is considered to weigh twice as much the benefits of a true positive call, the odds ratio is 2:1, i.e., 2/1 = 2). The standardized net benefit is net benefit divided by the prevalence of the outcome (the proportion of patients with critical illness in this study) (32) .

Analysis was conducted in IBM SPSS Statistics for Windows (Version 26.0; IBM, Armonk, NY) and R version 3.6.3 (R Foundation for Statistical Computing, Vienna, Australia). Results of the logistic regression are presented as adjusted odds ratios (ORs) with 95% confidence intervals (CIs). All tests were two-sided, a P-value < .05 was deemed statistically significant.

A total of 356 patients were included in the study (Figure 1 ), with 121/356 (34%) patients from hospital A and 235/345 (66%) patients from hospital B. Between the patients from the two participating centers, no significant differences were found for laboratory values, chest radiography score, or duration of symptoms before admission (Table 1 ). Mean patient age was 69 years (±12) and 237/356 (67%) were male. Median duration of symptoms was 7 days (range, 0-35 days). A full summary of patient characteristics per hospital is given in Tables E1 and E2 .

Of all included patients 168/356 (47%) developed critical illness (ICU admission and/or death). Of those 24/168 (14%) died at the ICU, 73/168 (44%) died at a COVID-19 cohort ward, and 71/168 (42%) patients were admitted to ICU but were alive at follow-up.

For all patients, the median duration of symptoms at admission was 7 days (range 0-35 days).

Median time-to-intubation from admission was 4 days (range, 0-18 days) and 8 days (range, 1-35 days) since the onset of symptoms. Median survival in the deceased population was 4 days (range, 0-30 days) after admission and 16 days (range, 4-39 days) since the onset of symptoms.

Patients who developed critical illness were significantly older ( [48%]; p=.08). No significant difference was found for body habitus on chest radiography (p=.12), temperature (p=.43), and the other comorbidities (Table 2) .

After backward elimination, the following variables remained in the model: male gender(adjusted OR 1.5, 95% CI 0.9-2.7, P=.10), obstructive lung disease (adjusted OR 1.9, 95% CI 1.0-3.5, P=.045), symptom duration > 7 days (adjusted OR 0.5, 95% CI 0.3-0.8, P=.003), (neutrophils/10) 3 

The risk score was developed using the regression coefficients of the logistic regression model (β) resulting in the following formula: probability = 1/(1+exp(-(intercept + gender × β + obstructive lung disease × β + > 7 days of symptoms × β + (neutrophils/10)^3 × β + (CRP/100)^-2 × β + (LDH/1000) × β + distribution × β + CXR score × β ))). The risk calculator can be accessed on line (hyperlink: Dutch COVID-19 risk model) (see Appendix E2).

The decision curve ( Figure 4 ) shows that our model (red line) provides a superior net benefit for risk thresholds of 0.5 or higher, equivalent to a cost-benefit ratio of 1:1 or greater in favor of patients who do not develop critical illness. For example, the risk score threshold of 0.70 (cost-benefit-ratio 7:3) is at the 80th percentile of the population, meaning that 20% of the population will get a positive test (i.e. positive for development of critical illness). In our study this is 71/356 (20%) patients. Of 

In this study we developed a risk model to predict short -term critical illness defined as ICU admission illness. This also explains why age, presence of severe symptoms (e.g., unconsciousness), or number of comorbidities were very strong predictors in their model and contributed to a high discriminatory predictive ability (AUC = 0.88). Our study population however was different and consisted exclusively of patients with severe disease who required hospital admission. Our population had a large proportion that developed critical illness (168/356; 47%). It is likely that the discriminatory ability of our model would improve when also applied to outpatients, since those patients would show less disease findings than our study population (26, 33) . Furthermore, Liang et al. included only one measure of abnormality on chest radiography (yes vs. no), despite it is known that the extent of lung involvement in viral pneumonia visible on chest radiography or CT may predict a worsened outcome (21-23, 25, 33, 34) . Moreover, we showed that the distribution of lung abnormalities on chest radiography provides additional prognostic information as well. Patients with diffuse or central lung I n P r e s s abnormalities, had higher odds for critical illness in our risk model than only peripheral abnormalities.

Although we included several chest radiography characteristics and laboratory markers in our analysis, we aimed to keep our risk model simple so that it can be used in resource limited areas. We chose to use chest radiography instead of CT and the scoring of the extent of disease on chest radiography was a simple semi-quantitative visual assessment, since estimation of the precise pulmonary involvement on chest radiography is challenging, especially from portable bedside chest radiographs. Secondly, we did not include many of the commonly used laboratory markers such as ferritin, procalcitonin, D-dimer, fibrinogen (3, 4, 6, 7, 11, 26) in our analysis, since some laboratory tests are not widely available or are expensive.

Besides providing accuracy measures such as AUC, sensitivity, and specificity, we also performed decision curve analysis. This method has been increasingly used to assess diagnostic tests and prediction models. The advantage of decision curve analysis is that it incorporates the preference of the physicians, patients, and/or policy makers into analysis. It weighs the benefits and costs at a certain threshold, i.e., the minimum event risk probability which defines a positive test outcome.

When ICU facilities are limited, one may prefer to predict critical illness with high specificity, i.e., a low false positive rate. We suggested a risk probability threshold of 0.70 using our model; this means that the early preparation for clinical deterioration would be justified if there were at least 2. There are a number of limitations to this work. Our prediction model has not been externally validated, and is based on a retrospective cohort of only 356 patients from two hospitals. We included known predictive parameters of worse outcome in patients with COVID-19 at the time of inclusion of our study population. However, we were not able to incorporate all known clinical parameters and laboratory values such as, body mass index, history of tobacco use, oxygenation levels at admission or pulmonary function, D-dimer, ferritin, mainly because they were not available for all patients during the peak of the pandemic.

Chest radiographs were independently analyzed by radiologists from their respective centers using a scoring system designed for this study, and heterogeneity among radiologists was unaccounted for.

However, no significant differences in chest radiography scoring were seen between centers with similar source populations, suggesting satisfactory inter-rater agreement.

Lastly, this study aimed to identify predictors and develop a risk model for critical illness in a setting where the knowledge regarding risk factors for critical illness in COVID-19 is still limited. The risk model shows good calibration and robustness upon internal validation (optimism = 0.026) and will therefore very likely perform well in a similar population. However, the performance may differ in other source populations.

In summary, we found that basic laboratory findings and a simple assessment of parenchymal involvement on a chest radiography acquired at hospital admission may provide complimentary information for short-term prognosis in hospitalized patients with coronavirus disease. We show that a simple model composed of gender, chronic obstructive lung disease, neutrophil granulocytes, Creactive protein, lactate dehydrogenase, distribution of lung abnormalities and a chest radiography I n P r e s s score were predictive of the need for mechanical ventilation/death among hospitalized patients with coronavirus disease. A risk calculator has been made available for download: Dutch COVID-19 risk model (Appendix E2). Multivariable logistic regression model for predicting short-term critical illness (ICU admission for invasive ventilation and/or death) in patients with coronavirus disease 2019 based on parameters obtained at admission. A calculator for this model is available for download (see Appendix E2). This table reports the model accuracy at various risk thresholds for predicting short-term critical illness (ICU admission for invasive ventilation and/or death) in hospitalized patients with coronavirus disease 2019. Fewer patients receive a positive test outcome at higher risk thresholds, though the ratio of true positives (i.e., critical ill patients) compared to false positives (i.e., non-critical ill patients) increases. A positive standardized net benefit (sNB) value indicates that applying the model at that threshold is superior to a scenario where all patients are assumed to not develop critical illness ( Figure 4) ; this is not necessarily superior to a scenario where all patients are assumed to develop critical illness. Please refer to Appendix E3 for a more detailed explanation for interpreting sNB. Abbreviations: PPV, positive predictive value; NPV, negative predictive value; sNB, standardized net benefit. I n P r e s s I n P r e s s The output of risk prediction models is the probability that an event will happen given a set of predictor variables. Using the Dutch coronavirus disease 2019 (COVID-19) risk model as an example, the probability that hospitalized patients with COVID-19 will develop critical illness is based on the predictors given in Table 3 . The standard reported measure of risk model performance is the area under the receiver operating characteristic curve (AUC). In this case, AUC should be interpreted as the probability that a patient which encounters critical illness has a greater risk probability than a patient which does not. Although simple to understand and interpret, AUC is not informative as to its clinical value (1). This is because AUC does not consider whether it is preferable to have falsenegative or false-positive results. For example, in a scenario where there are limited intensive care unit (ICU) spaces, a patient who does not develop critical illness but who is immediately assigned to an ICU bed at admission (false positive) may be considered to be less desirable than a patient who does develop critical illness but for who an ICU bed was not immediately reserved. Note that this is a measure of subjective preference which varies among physicians and patients.

Decision curve analysis was introduced as a discriminatory metric for models which considers such clinical consequences (2) (3) (4) . A key aspect of decision curves is the concept of net benefit. This is a calculation which involves determining the difference between the benefits (i.e., correctly predicting that a hospitalized patient with COVID-19 will develop critical illness [true positive rate]) and costs (i.e., incorrectly predicting that a patient will develop critical illness [false positive rate]) of the intervention. As indicated, the relative weighting of the costs and benefits this is a subjective measure of preference which is equivalent to the risk probability threshold. A higher probability threshold will reduce both the number of patients at "high risk" with and without the event, i.e., the true and false positive rates, respectively ( Figure E2 ). For a model with some predictive ability, this would also result in proportionally more patients with high risk ( Figure E3 ). We suggested a probability threshold of 0.70 for the Dutch COVID-19 risk model, meaning that only patients with a critical illness risk greater of 70% were predicted to develop critical illness. In this case, a false positive result weighs heavier than a true positive result with an odds of 7:3 ( ).

Finally, by adjusting the true positive rate and false positive rate with the prevalence of the event of interest (critical illness) is then possible to calculate the net benefit using the following equation:

Note that net benefit may be difficult to interpret because the maximum possible value is the event prevalence (i.e., when true positive rate = 1 and false positive rate = 0). It is therefore commonplace to calculate the standardized net benefit by dividing net benefit by the event prevalence. This may simplify the interpretation because standardized net benefit always has a maximum possible value of 1. At a risk probability threshold of 0.70, a standardized net benefit of 0.18 was calculated (Table 4) . This can be interpreted as follows: compared to no intervention (all hospitalized patients with COVID-19 are assumed to not develop critical illness), 18% more of the patients which develop critical illness would be correctly predicted (true positives) without additional incorrect predictions among the patients which do not (false positives). Figure 4 shows the decision curve of the Dutch COVID-19 risk model, where the standardized net benefit is given on the y-axis and the probability threshold (i.e., cost:benefit odds ratio) on the x-axis. Besides the performance of the proposed model (red line), it is also typical to include the decision curves for a policy where all hospitalized patients with COVID-19 are assumed to develop critical illness (grey line) or none at all (horizontal black line). In short, the proposed model can be of added value in the clinic at probability thresholds where its standardized net benefit is greater than that of the two other lines.

For a more detailed guide to the correct use and interpretation of decision curve analysis, please refer to Kerr 

An interactive web-based dashboard to track COVID-19 in real time

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, china

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, china

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, china: A descriptive study

China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in china

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, china: A retrospective cohort study

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, china

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and metaanalysis

COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis

The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients

HLH Across Specialty Collaboration, UK. COVID-19: Consider cytokine storm syndromes and immunosuppression

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, china. Intensive Care Med

Prognostic value of NT-proBNP in patients with severe COVID-19

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, china

Mild versus severe COVID-19: Laboratory markers

Radiological society of north America expert consensus statement on reporting chest CT findings related to COVID-19. Endorsed by the society of thoracic radiology, the American college of radiology, and RSNA

Diagnostic performance of CT and reverse transcriptase-polymerase chain reaction for coronavirus disease 2019: A meta-analysis

Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in china: A report of 1014 cases

The role of chest imaging in patient management during the COVID-19 pandemic: A multinational consensus statement from the Fleischner society

Value of initial chest radiographs for predicting clinical outcomes in patients with severe acute respiratory syndrome

Chest radiograph scores as potential prognostic indicators in severe acute respiratory syndrome (SARS)

Severe acute respiratory syndrome (SARS): Epidemiology and clinical features

Clinical implication of radiographic scores in acute Middle East respiratory syndrome coronavirus pneumonia: Report from a single tertiaryreferral center of South Korea

Acute middle east respiratory syndrome coronavirus: Temporal lung changes observed on the chest radiographs of 55 patients

China Medical Treatment Expert Group for, COVID-19. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19

written on behalf of AME Big-Data Clinical Trial Collaborative Group. Decision curve analysis: A technical note

PROBAST: A tool to assess risk of bias and applicability of prediction model studies: Explanation and elaboration

Clinical prediction models: a practical approach to development, validation, and updating

Assessing the clinical impact of risk prediction models with decision curves: Guidance for correct interpretation and appropriate use

Clinical and chest radiography features determine patient outcomes in young and middle age adults with COVID-19

Computed tomographic features and shortterm prognosis of coronavirus disease 2019 (COVID-19) pneumonia: A single-center study from kashan, iran. Radiology: Cardiothoracic Imaging

Traditional Statistical Methods for Evaluating Prediction Models Are Uninformative as to Clinical Value: Towards a Decision Analytic Framework

Decision curve analysis: A novel method for evaluating prediction models

Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use

A simple, step-by-step guide to interpreting decision curve analysis

I n P r e s s .39

.27